Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
source https://finance.yahoo.com/news/lillys-ret-inhibitor-shrinks-tumors-203908947.html?.tsrc=rss
blaineonline.finance.blog 